Parenteral are sterile dosage form that are administered through route other than oral route of administration. They are injected into one or more layer of skin and active ingredient directly come in contact with tissue or blood vessel. Large volume parenteral are of two types, small volume parenteral are single or multi dosage preparation with volume 100 ml or less quantity whereas large volume parenteral has volume more than 100 ml. Large volume parenteral comes in bag or bottle for intravenous administration and are used for correction of fluid/electrolyte balance, providing nutrition such as dextrose.
Increased need of palliative care and need for more surgical procedures to drive growth of the large volume parenteral market
Increasing demand for palliative care worldwide is expected to drive growth of the large volume parenteral market, owing to use of large volume parenteral to provide electrolyte balance and nutritional fluids. According to World Health Organization (WHO), 2017, an estimate of 40 million people need palliative care worldwide. Around 78% among those people, live in low- and middle-income economies and only 14% of people in need of palliative care receives it. Disease which require high palliative care are cardiovascular diseases (38.5%), cancer (34%), chronic respiratory diseases (10.3%), AIDS (5.7%) and diabetes (4.6%), kidney failure, chronic liver disease. This creates potential opportunity for large volume parenteral market players. Increasing number of surgeries are expected to propel growth for the large volume parenteral market worldwide. For instance, according to World Bank statistics, in 2012, around 4511 surgeries were performed per 1,00,000 population across the globe. As per Lancet Commission for Global Surgery, 2015, an estimate of 143 million unmet surgical need per year, surgical need in turn drives large volume parenteral market as they are essential part of pre and post-operative care.
Large Volume Parenteral Market Taxonomy:
On the basis of application:
On the basis of end user:
Regional segmentation of the large volume parental market by Coherent Market Insights consist of North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to dominate the large volume parenteral market, owing to increasing number of hospital admissions and cost associated with such admission (an estimated US$ 1900 in 2013 as per Kaiser Health fact). According to American Hospital Association factsheet 2018, an estimated 35,158,934 hospital admissions were reported in 2017, large volume parenteral is integral part of any admission procedure, as nutrition and electrolyte support is essential in most of the cases. According to report by Lancet Commission for Global Surgery, 2015, large number of unmet surgical needs in Asia Pacific region are expected to provide potential opportunity for large volume parenteral market due to use of large volume parenteral to administer therapeutics doses or nutrition. Parenteral nutrition plays a key role in patients who are unable to take diet normally or unconscious. In such cases nutrition is administered through large volume parenteral. According to study published in Journal of Critical Care in 2017, an estimate of 40,000 people are in need of such parenteral nutrition annually in the U.S., which in turn is driving growth of the market.
Key players operating in large volume parenteral market include Baxter International Inc., Teva Pharmaceutical Industries Limited, Kelun Pharmaceutical Inc., BAG Healthcare GmbH, Hospira, Inc., Patheon Inc., Otsuka Pharmaceutical, Wockhardt Ltd., Southwest Pharmaceutical Co. Ltd., and Cook Pharmica LLC.
In January 2018, Baxter International Inc. announced a distribution agreement for the U.S. launch of the Arisure Closed System Transfer device, which has several component to prevent contaminants from entering the intravenous medication delivery system. This avoids the entry of hazardous substances while administration of therapy. Baxter International Inc. also completed the acquisition of the Claris Injectable Limited in July 2017, which is expected to improve Baxter’s presence in generic injectable market.